Mindpeak: First Patent for Advanced AI Method in Digital Pathology

Patent covers novel approach for training AI systems and classifying cells in oncologic histopathological tissue diagnostics

Mindpeak is thrilled to announce that it has been granted its first patent, covering a groundbreaking novel way to train an AI system so it can accurately spot and classify different cells in tissue samples in medical diagnosis. The patent, issued in 17 EU member states and additionally validated in the United Kingdom, marks a major milestone in Mindpeak’s mission to advance precision diagnostics in oncology.

“This is a defining moment for Mindpeak as our first patent underscores the scientific and technological strength of our approach to AI in digital pathology”, said Felix Faber, Founder and CEO of Mindpeak. (Image: Mindpeak)
“This is a defining moment for Mindpeak as our first patent underscores the scientific and technological strength of our approach to AI in digital pathology”, said Felix Faber, Founder and CEO of Mindpeak. (Image: Mindpeak)

The newly granted patent – ‘Method for training an artificial intelligence system for recognising and classifying cells for pathological cell and tissue examination, classifying system, computer-readable medium’ - protects Mindpeak’s proprietary approach for developing AI models capable of recognising and classifying individual cells within complex pathology images. This method enables unprecedented accuracy, robustness and consistency in digital workflows.

“This is a defining moment for Mindpeak as our first patent underscores the scientific and technological strength of our approach to AI in digital pathology”, said Felix Faber, Founder and CEO of Mindpeak. “The patent provides the foundation for scalable applications across oncology and for improved pathology quality and reproducibility. We’re proud of this patent, which reinforces our commitment to delivering clinically reliable AI solutions worldwide to get the right treatment to patients faster.”

Mindpeak’s patented method introduces innovations in both the model training architecture and the cell classification process. These advances enable the AI system to learn from heterogeneous datasets, adapt to variations in staining and sample preparation and deliver consistent outputs across laboratories and scanner platforms, addressing several key challenges in routine pathology.

“Our research teams have worked tirelessly to overcome the limitations of current digital pathology technologies and this patent reflects the depth of scientific innovation behind our models,” said Theresa Koehler, Research and Development Innovation Manager at Mindpeak. “It is impressive to see our technical concepts shaped through the legal process into a form that stands up internationally.”

More News

Dr. Fernando Delgado (CTO), Dr. Michael Hartung (CPO), Alexander Zahn (CEO), and Prof. Dr. Jan Baumbach (CSO) (from left) founded the company in Hamburg in 2025. (Photo: Galagos)
Dr. Fernando Delgado (CTO), Dr. Michael Hartung (CPO), Alexander Zahn (CEO), and Prof. Dr. Jan Baumbach (CSO) (from left) founded the company in Hamburg in 2025. (Photo: Galagos)

#NEWatLSN: Galagos

We are delighted to welcome Galagos as a new member of Life Science Nord e.V.! The founding team answered questions about the company’s initial goals, ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
Onco AI-Med meeting at Indivumed: Dr. David Kerr, Nils Schumacher, Prof. Gerry Melino, Nina Gabelia, Dr. John Marshall, Dr. Takayuki Yoshino, Prof. Hartmut Juhl, Dr. Sun Young Rha, Dr. Jesus Garcia-Foncillas, Dr. Carlos Sampaio and Dr. David Gallagher (fr
Onco AI-Med meeting at Indivumed: Dr. David Kerr, Nils Schumacher, Prof. Gerry Melino, Nina Gabelia, Dr. John Marshall, Dr. Takayuki Yoshino, Prof. Hartmut Juhl, Dr. Sun Young Rha, Dr. Jesus Garcia-Foncillas, Dr. Carlos Sampaio and Dr. David Gallagher (from left to right) (Picture: Indivumed)

Indivumed Hosts Onco AI-Med Annual Board Meeting in Hamburg

Indivumed Therapeutics (“Indivumed”) welcomed members of the Oncology Alliance For Individualized Medicine (“Onco AI-Med”) to its global headquarters in Hamburg, ...

Read more …